Logo image of VYNT

VYANT BIO INC (VYNT) Stock Fundamental Analysis

NASDAQ:VYNT - Nasdaq - US92942V2088 - Common Stock - Currency: USD

0.26  -0.08 (-23.51%)

After market: 0.2211 -0.04 (-14.96%)

Fundamental Rating

1

Overall VYNT gets a fundamental rating of 1 out of 10. We evaluated VYNT against 566 industry peers in the Biotechnology industry. Both the profitability and financial health of VYNT have multiple concerns. VYNT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VYNT has reported negative net income.
VYNT had a negative operating cash flow in the past year.
In the past 5 years VYNT always reported negative net income.
In the past 5 years VYNT always reported negative operating cash flow.
VYNT Yearly Net Income VS EBIT VS OCF VS FCFVYNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

VYNT has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VYNT Yearly ROA, ROE, ROICVYNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VYNT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VYNT Yearly Profit, Operating, Gross MarginsVYNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

VYNT does not have a ROIC to compare to the WACC, probably because it is not profitable.
VYNT has more shares outstanding than it did 1 year ago.
The debt/assets ratio for VYNT is higher compared to a year ago.
VYNT Yearly Shares OutstandingVYNT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
VYNT Yearly Total Debt VS Total AssetsVYNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -11.95, we must say that VYNT is in the distress zone and has some risk of bankruptcy.
VYNT has a worse Altman-Z score (-11.95) than 80.35% of its industry peers.
VYNT has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.03, VYNT perfoms like the industry average, outperforming 40.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -11.95
ROIC/WACCN/A
WACC8.02%
VYNT Yearly LT Debt VS Equity VS FCFVYNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M 30M

2.3 Liquidity

VYNT has a Current Ratio of 3.14. This indicates that VYNT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.14, VYNT is doing worse than 69.89% of the companies in the same industry.
A Quick Ratio of 3.13 indicates that VYNT has no problem at all paying its short term obligations.
With a Quick ratio value of 3.13, VYNT is not doing good in the industry: 68.94% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 3.13
VYNT Yearly Current Assets VS Current LiabilitesVYNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

VYNT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -101.61%.
VYNT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.19%.
VYNT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -53.03% yearly.
EPS 1Y (TTM)-101.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-260.59%
Revenue 1Y (TTM)-86.19%
Revenue growth 3Y-55%
Revenue growth 5Y-53.03%
Sales Q2Q%-95.99%

3.2 Future

The Earnings Per Share is expected to grow by 19.54% on average over the next years. This is quite good.
The Revenue is expected to decrease by -41.42% on average over the next years. This is quite bad
EPS Next Y37.93%
EPS Next 2Y19.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VYNT Yearly Revenue VS EstimatesVYNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
VYNT Yearly EPS VS EstimatesVYNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VYNT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYNT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VYNT Price Earnings VS Forward Price EarningsVYNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VYNT Per share dataVYNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

VYNT's earnings are expected to grow with 19.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VYNT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VYANT BIO INC

NASDAQ:VYNT (5/12/2023, 8:07:00 PM)

After market: 0.2211 -0.04 (-14.96%)

0.26

-0.08 (-23.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2023-05-15
Earnings (Next)08-14 2023-08-14
Inst Owners0%
Inst Owner Change0%
Ins Owners7.2%
Ins Owner Change0%
Market Cap1.63M
Analysts82.86
Price Target5.1 (1861.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.73%
Min EPS beat(2)-15.91%
Max EPS beat(2)17.37%
EPS beat(4)1
Avg EPS beat(4)-31.33%
Min EPS beat(4)-96.08%
Max EPS beat(4)17.37%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)99.64%
Min Revenue beat(2)87.91%
Max Revenue beat(2)111.38%
Revenue beat(4)2
Avg Revenue beat(4)44.8%
Min Revenue beat(4)-19.12%
Max Revenue beat(4)111.38%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-46.01%
EPS NY rev (3m)-77.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.45
P/FCF N/A
P/OCF N/A
P/B 0.16
P/tB 0.16
EV/EBITDA N/A
EPS(TTM)-3.91
EYN/A
EPS(NY)-2.43
Fwd EYN/A
FCF(TTM)-2.28
FCFYN/A
OCF(TTM)-2.18
OCFYN/A
SpS0.11
BVpS1.58
TBVpS1.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.14
Quick Ratio 3.13
Altman-Z -11.95
F-Score2
WACC8.02%
ROIC/WACCN/A
Cap/Depr(3y)73.94%
Cap/Depr(5y)45.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-101.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-260.59%
EPS Next Y37.93%
EPS Next 2Y19.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-86.19%
Revenue growth 3Y-55%
Revenue growth 5Y-53.03%
Sales Q2Q%-95.99%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.49%
OCF growth 3YN/A
OCF growth 5YN/A